Processes for preparing cyclopenta[b]naphthalenol derivatives and intermediates thereof

Abstract

Novel processes for preparing cyclopenta[b]naphthalenol derivatives of Formula 1 ##STR00001##
which are useful for the synthesis of corresponding benzindene prostaglandins are provided. The present invention also relates to novel intermediates prepared from the processes.

Claims

1. A process for preparing a compound of Formula 1: ##STR00014## wherein R.sub.1 is a single bond, C.sub.1-4-alkylene or CH.sub.2O; R.sub.2 is C.sub.1-7-alkyl, aryl or aralkyl, each of which is unsubstituted or substituted by C.sub.1-4-alkyl, halogen or trihalomethyl; P.sub.2 and P.sub.3 are the same or different protecting groups for the hydroxyl groups; and is a single bond or a double bond, comprising reacting a compound of Formula 2: ##STR00015## wherein X is a sulfonyl group; R.sub.1, R.sub.2, , P.sub.2 and P.sub.3 are as defined above, with a base.

2. The process according to claim 1, wherein the sulfonyl group is methanesulfonyl or p-toluenesulfonyl.

3. The process according to claim 1, wherein the base is selected from sodium hydride, potassium hydride, lithium hydride, potassium tert-butoxide and butyllithium.

4. A process for preparing a compound of Formula 1: ##STR00016## wherein R.sub.1 is a single bond, C.sub.1-4-alkylene or CH.sub.2O; R.sub.2 is C.sub.1-7-alkyl, aryl or aralkyl, each of which is unsubstituted or substituted by C.sub.1-4-alkyl, halogen or trihalomethyl; P.sub.2 and P.sub.3 are the same or different protecting groups for the hydroxyl groups; and is a single bond or a double bond, comprising the steps of (a) sulfonylation of a compound of Formula 3 ##STR00017## in the presence of a first base with a sulfonyl donor to form a compound of Formula 2, ##STR00018## wherein X is a sulfonyl group; R.sub.1, R.sub.2, , P.sub.2 and P.sub.3 are as defined above, and (b) intramolecular alkylation of the compounds of Formula 2 in the presence of a second base to form the compound of Formula 1.

5. The process according to claim 4, wherein the sulfonyl donor is methanesulfonyl chloride or p-toluenesulfonyl chloride.

6. The process according to claim 4, wherein the sulfonyl group is methanesulfonyl or p-toluenesulfonyl.

7. The process according to claim 4, wherein the first base is selected from sodium hydride, potassium hydride, lithium hydride, pyridine, triethylamine, N,N-Diisopropylethylamine and imidazole.

8. The process according to claim 4, wherein the second base is selected from sodium hydride, potassium hydride, lithium hydride, potassium tert-butoxide and butyllithium.

9. A compound of Formula 3 ##STR00019## wherein R.sub.1 is a single bond, C.sub.1-4-alkylene or CH.sub.2O; R.sub.2 is C.sub.1-7-alkyl, aryl or aralkyl, each of which is unsubstituted or substituted by C.sub.1-4-alkyl, halogen or trihalomethyl; P.sub.2 and P.sub.3 are the same or different protecting groups for the hydroxyl groups, and is a single bond or a double bond.

10. The compound of claim 9, wherein R.sub.1 is methylene and R.sub.2 is n-butyl.

Description

DETAILED DESCRIPTION OF THE INVENTION

(1) Herein, unless otherwise specified, the term alkyl refers to an aliphatic hydrocarbon group which may be straight or branched having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 6 carbon atoms, in the chain, such as methyl, ethyl, n-propyl, iso-propyl, t-butyl, and the like; the term aryl refers to a monocyclic or polycyclic aromatic hydrocarbon radical, such as phenyl, naphthyl, anthryl, phenanthryl and the like, which may optionally be substituted with one or more substituents, including but not limited to, halogen, alkoxyl, thioalkoxyl, alkyl, and aryl; and the term aralkyl refers to a straight or branched hydrocarbon containing 1 to 20 carbon atoms and one or more aryl group as described above, such as benzyl, benzhydryl, fluorenylmethyl, and the like.

(2) When a defined radical is substituted, the substituent is selected from the group consisting of halogen, alkyl, aryl, alkoxyl, aryloxy, thioalkoxyl, thioaryloxy, alkylamino, arylamino, cyano, nitro, alkoxycarbonyl, arylcarbonyl, arylaminocarbonyl, alkylaminocarbonyl, and carbonyl or a heterocyclic group selected from the group consisting of pyridinyl, thiophenyl, pyranyl, furanyl, imidazolyl, morpholinyl, oxazolinyl, piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidinyl, pyrrolidinonyl, and the like, and the combinations thereof.

(3) In the depiction of the compounds given throughout this description, a thickened taper line () indicates a substituent in the beta-orientation (above the plane of the molecule or page), and a broken flare line () indicates a substituent in the alpha-orientation (below the plane of the molecule or page).

(4) According to one aspect and as shown in the following Scheme C, there is provided a process for preparing the compound of Formula 1

(5) ##STR00007##
wherein R.sub.1 is a single bond, C.sub.1-4-alkylene or CH.sub.2O; R.sub.2 is C.sub.1-7-alkyl, aryl or aralkyl, each of which is unsubstituted or substituted by C.sub.1-4-alkyl, halogen or trihalomethyl; P.sub.2 and P.sub.3 are same or different protecting groups for the hydroxyl group; and is a single bond or a double bond, prepared from cyclopentanes of Formula 4 wherein P.sub.1 is a protecting group for the phenol group.

(6) Suitable protecting groups for the phenol group are preferably acid stable and include, but are not limited to, unsubstituted or substituted alkyl, allyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclic group, acetyl, and alkylcarbonyl, for example, benzyl, methoxymethyl, methoxythiomethyl, 2-methoxyethoxymethyl, bis(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, triphenylmethyl, and SiR.sub.aR.sub.bR.sub.c wherein R.sub.a, R.sub.b and R.sub.c are each independently unsubstituted or substituted alkyl, unsubstituted or substituted aryl or acetyl, such as phenyl, benzyl, substituted phenyl and substituted benzyl; and more preferably P.sub.1 is selected from unsubstituted or substituted benzyl and SiR.sub.aR.sub.bR.sub.c wherein R.sub.a, R.sub.b and R.sub.c are each independently alkyl or alkylcarbonyl.

(7) Suitable protecting groups for the hydroxyl group are the same or different and are preferably base stable, and include, but are not limited to, methoxymethyl, methoxythiomethyl, 2-methoxyethoxymethyl, bis(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, triphenylmethyl, and SiR.sub.aR.sub.bR.sub.c wherein R.sub.a, R.sub.b and R.sub.c are each independently unsubstituted or substituted alkyl or unsubstituted or substituted aryl, such as phenyl, benzyl, substituted phenyl and substituted benzyl.

(8) ##STR00008##

(9) As shown in Step (a) of Scheme C, the compound of Formula 4 is subjected to a deprotection reaction or subjected to the deprotection reaction together with a hydrogenation of the double bond of the co-side chain for replacing P.sub.1 with H. The conditions suitable for the deprotection depend on the variable of P.sub.1. When P.sub.1 is trialkylsilyl, the deprotection reaction is achieved by using a fluoride ion, such as tetra-butylammonium fluoride. When P.sub.1 is unsubstituted or substituted benzyl, the deprotection reaction is achieved by using a hydrogenation catalyst in a suitable solvent and in the presence of hydrogen. Suitable hydrogenation catalyst contains a metal selected from the group consisting of palladium, platinum, rhodium, and nickel and a mixture thereof. Examples of the catalyst include Pd/C, Pt/C, and Ni. Suitable solvent can be selected from tetrahydrofuran, ethyl acetate, methanol, ethanol, toluene, and a mixture thereof. In one embodiment, for the compound of Formula 4 where P.sub.1 is unsubstituted or substituted benzyl and is a double bound, the hydrogenation may be ended with obtaining a diol compound of Formula 3 where is a double bound, or may be continuously proceeded to obtain a diol compound of Formula 3 where is a single bound, as monitored by HPLC or TLC.

(10) As shown in Step (b) of Scheme C, the diol compound of Formula 3 is further subjected to a sulfonylation reaction to obtain a cyclopentane compound of Formula 2 wherein X is a sulfonyl group which is unsubstituted or substituted, including, but not limited to alkylsulfonyl, arylsulfonyl or aralkylsulfonyl, such as methanesulfonyl or p-toluenesulfonyl. The sulfonylation reaction is achieved in the presence of a base, such as an amine, e.g., triethylamine or N,N-diisopropylethylamine; or an nitrogen-containing heterocyclic compound, e.g., pyridine or imidazole; or an alkali metal hydride, e.g., sodium hydride, potassium hydride or lithium hydride, by using an appropriate sulfonyl donor, such as methanesulfonyl chloride or p-toluenesulfonyl chloride. In Step (b), based on the structure of the compound of Formula 3, the hydroxy group on the phenyl group has higher activity than that on the primary alcohol and thus will be primarily subjected to the sulfonylation reaction so as to form the compound of Formula 2. If an excess amount of the sulfonyl donors is used, a disulfonyl compound of Formula 2c

(11) ##STR00009##
wherein X is alkylsulfonyl, arylsulfonyl or aralkylsulfonyl is obtained

(12) The side products, the disulfonyl compound of Formula 2c, can be removed by a conventional method, such as column chromatography. However, since both of the main products of Formula 2 and the side products of Formula 2c can undergo the subsequent intramolecular alkylation for forming the compound of Formula 1, it is unnecessary to remove the side products, e.g., the disulfonyl compound of Formula 2c at this stage.

(13) As shown in Step (c) of Scheme C, the compound of Formula 2 or the mixture of the compound of Formula 2 and the compound of Formula 2c is further subjected to an intramolecular alkylation so as to form the compound of Formula 1. The intramolecular alkylation is achieved by using a suitable base in a suitable solvent. Suitable base can be selected from sodium hydride, potassium hydride, lithium hydride, potassium tert-butoxide, butyllithium, and a mixture thereof. Suitable solvent can be selected from tetrahydrofuran, 2-methyl tetrahydrofuran, glyme, toluene, and a mixture thereof.

(14) In the aforementioned prior art procedures as shown in Scheme A and Scheme B, the intramolecular alkylation is carried out on the sulfonyl group on the primary alcohol of the compounds of Formulae 2a and 2b. However, the present inventors have unexpectedly found that the intramolecular alkylation can also be carried out on the sulfonyl group on the phenol group of the compound of Formula 2.

(15) It has also been surprisingly found that the novel process produces the product with a higher yield and reduced cost. Specifically, a large amount (about 30 to 40% w/w) of expensive hydrogenation catalysts has to be used in Step b of Scheme B of the aforementioned prior art process; however, in the novel process, only about 5 to 10% w/w of the hydrogenation catalyst is used in Step (a) of Scheme C, the benzyl groups can be rapidly removed. Moreover, the aforementioned side reactions in Step b of Scheme B can be completely avoided in the novel processes, thereby the drawbacks associated with the prior processes can be effectively solved.

(16) The present invention further pertains to a novel compound of Formula 3a

(17) ##STR00010##
wherein R.sub.1 is a single bond, C.sub.1-4-alkylene or CH.sub.2O, preferably methylene; R.sub.2 is C.sub.1-7-alkyl, aryl or aralkyl, preferably n-butyl, each of which is unsubstituted or substituted by C.sub.1-4-alkyl, halogen or trihalomethyl; P.sub.2 and P.sub.3 are the same or different protecting groups for the hydroxyl groups; and is a single bond or a double bond.

(18) The following examples are used to further illustrate the present invention, but are not intended to limit the scope of the present invention. Any modifications or alterations that can be easily accomplished by persons skilled in the art fall within the scope of the disclosure of the specification and the appended claims.

EXAMPLES

Example 1

3-(((1S,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((S,E)-3-(tert-butyldimethyl-silyloxy)oct-1-enyl)-5-(hydroxymethyl)cyclopentyl)methyl)phenol

(19) ##STR00011##

(20) A solution of ((1S,2S,3R,4R)-2-(3-(benzyloxy)benzyl)-4-(tert-butyldimethyl-silyloxy)-3-((S,E)-3-(tert-butyldimethylsilyloxy)oct-1-enyl)cyclopentyl)methanol (10 g, 15 mmol) in methanol (200 ml) was treated with potassium hydroxide (2.2 g, 40 mmol) and 5% Pd/C (1 g, 10% wt) under hydrogen for 1 hour. After the reaction was completed, the reaction mixture was filtered with celite pad and washed with methanol. Then, the pH value of the mixture was adjusted to 8.5 with 2M a sodium bisulfate aqueous solution. The solvent was evaporated. The resulting residue was dissolved in water and extracted with ethyl acetate. After separating, the organic layer was washed with brine and dried over anhydrous magnesium sulfate. The solid was filtered off. The organic solvent was evaporated off under vacuum. The crude product was purified by chromatography on silica gel using a mixture of hexane and ethyl acetate as a gradient eluent. Yield: 95%

(21) .sup.1H-NMR (CDCl.sub.3): 7.107 (t, 1H), 6.732 (d, 1H), 6.697 (s, 1H), 6.650 (d, 1H), 6.348 (br s, 1H), 5.495-5.373 (m, 2H), 4.066-4.038 (m, 2H), 3.809 (s, 2H), 3.670-3.648 (m, 1H), 2.821-2.694 (m, 2H), 2.377-2.333 (m, 1H), 2.119-2.006 m, 3H), 1.605-1.246 (m, 9H), 0.907-0.856 (m, 21H), 0.079-0.031 (m, 12H)

(22) .sup.13C-NMR (CDCl.sub.3): 56.150, 143.458, 135.018, 131.094, 129.424, 120.338, 115.776, 112.846, 79.183, 73.080, 63.547, 58.613, 49.239, 41.459, 40.533, 38.589, 34.642, 31.842, 25.929, 25.777, 25.101, 22.634, 18.300, 17.906, 14.042, 4.205, 4.463, 4.752, 4.805

Example 2

3-(((1S,2R,3R,5S)-3-((ter-butyldbutyldimethylsilyl)oxy)-2-((S,E)-3-((tert-butyldimethylsilyl) oxy)oct-1-en-1-yl)-5-(hydroxymethyl)cyclopentyl)methyl)phenyl methanesulfonate

(23) ##STR00012##

(24) A solution of 3-(((1S,2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-2-((S,E)-3-(tert-butyldimethylsilyloxy)oct-1-enyl)-5-(hydroxymethyl)cyclopentyl)methyl)phenol (1.0 g, 1.7 mmol) in dichloromethane (30 ml) was treated with triethylamine (0.35 g, 3.5 mmol) and the reaction mixture was cooled to 10 C. Then, mesyl chloride (0.24 g, 2.0 mmol) was added into the mixture and the mixture was warmed to room temperature. After 30 minutes, the resulting mixture was cooled down to 0 C. and saturated sodium bicarbonate was poured into. The mixture solution was separated and the organic layer was washed with brine. The solvent was dried over anhydrous magnesium sulfate. The solid was filtered off. The organic solvent was evaporated off under vacuum. The crude product was purified by chromatography on silica gel. Yield: 90%.

(25) .sup.1H-NMR (CDCl.sub.3): 7.294 (t, 1H), 7.169 (d, 1H), 7.127 (s, 1H), 7.090 (d, 1H), 5.463-5.353 (m, 2H), 4.062-4.020 (m, 2H), 3.719 (br s, 1H), 3.648-3.619 (m, 1H), 3.375 (br s, 1H), 3.112 (s, 3H), 2.851 (d, 2H), 2.377-2.342 (m, 1H), 2.117-1.973 (m, 3H), 1.608-1.256 (m, 9H), 0.896-0.850 (m, 21H), 0.073-0.031 (m, 12H)

(26) .sup.13C-NMR (CDCl3): 149.326, 144.536, 135.223, 130.927, 129.712, 127.693, 122.069, 119.177, 79.092, 72.928, 63.600, 58.484, 49.163, 41.565, 40.502, 38.597, 37.322, 34.491, 31.826, 29.261, 27.394, 25.906, 25.769, 25.063, 22.634, 18.278, 17.883, 14.035, 13.716, 8.736, 4.236, 4.463, 4.744, 4.812

Example 3

(1R,2R,3aS,9aS)-2-(tert-butyldimethylsilyloxy)-1-((S,E)-3-(tert-butyldimethyl-silyloxy) oct-1-enyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-ol

(27) ##STR00013##

(28) A solution of 3-(((1S,2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-2-((S,E)-3-((tert-butyl dimethylsilyl)oxy)oct-1-en-1-yl)-5-(hydroxymethyl)cyclopentyl)methyl)phenyl methanesulfonate (0.5 g, 0.8 mmol) in anhydrous THF (7.5 ml) at 10 C. under nitrogen was treated with 60% sodium hydride (90 mg, 2.4 mmol). The resulting suspension was stirred over 16 hours at 70 C. The reaction was diluted with ice cold brine and extracted. The reaction mixture was phase separated and the aqueous layer was extracted with ethyl acetate. The organic layers were combined and dried over anhydrous magnesium sulfate. The solid was filtered off. The solvent was evaporated off under vacuum. The crude product was purified by chromatography on silica gel using a mixture of hexane and ethyl acetate as a gradient eluent. Yield: 87%.

(29) .sup.1H-NMR (CDCl3): 6.991 (t, 1H), 6.712 (d, 1H), 6.652 (d, 1H), 5.536-5.439 (m, 2H) 5.006 (br s, 1H), 4.150-4.081 (m, 1H), 3.809-3.746 (m, 1H), 2.672 (dt, 2H), 2.502 (dd, 1H), 2.429 (dd, 1H), 2.332-2.265 (m, 1H), 2.159-2.095 (m, 1H), 2.001-1.845 (m, 2H), 1.531-1.158 (m, 9H), 0.919-0.835 (m, 21H), 0.061-0.024 (m, 12H)

(30) .sup.13C-NMR (CDCl3): 52.514, 140.938, 135.094, 130.646, 126.213, 124.513, 120.619, 112.945, 73.149, 55.835, 41.406, 39.857, 38.658, 32.601, 32.221, 31.864, 25.959, 25.936, 25.192, 22.657, 18.278, 18.202, 14.073, 4.167, 4.494, 4.524, 4.706